|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:bfsLayer
|
3
|
|
gptkbp:bfsParent
|
gptkb:Regeneron_Pharmaceuticals
|
|
gptkbp:acquisition
|
Acquired by Astellas Pharma
|
|
gptkbp:awards
|
Best Places to Work 2020
Top 10 Biotech Companies 2021
Fastest Growing Companies 2022
|
|
gptkbp:clinical_trial
|
gptkb:DB-OTO
Phase 1
Phase 2
Phase 3
DB-020
|
|
gptkbp:collaborations
|
gptkb:Harvard_Medical_School
gptkb:University_of_California,_San_Francisco
gptkb:Massachusetts_Eye_and_Ear
|
|
gptkbp:employees
|
50-100
|
|
gptkbp:focus
|
hearing loss
|
|
gptkbp:founded
|
gptkb:2013
|
|
gptkbp:founder
|
gptkb:Laurie_Glimcher
|
|
gptkbp:governed_by
|
gptkb:Dr._John_A._Mc_Carty
gptkb:Dr._Emily_R._Smith
gptkb:Mr._David_L._Brown
|
|
gptkbp:headquarters
|
gptkb:Boston,_Massachusetts
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Decibel Therapeutics
|
|
gptkbp:investment
|
gptkb:New_Enterprise_Associates
gptkb:Sofinnova_Partners
gptkb:Canaan_Partners
gptkb:Orbi_Med_Advisors
|
|
gptkbp:language_of_instruction
|
DB-020 for cisplatin-induced hearing loss
DB-301 for age-related hearing loss
DB-OTO for genetic hearing loss
|
|
gptkbp:leadership
|
gptkb:Kevin_H._O'_Connor
|
|
gptkbp:mission
|
transform the lives of people with hearing loss
|
|
gptkbp:partnership
|
gptkb:Johns_Hopkins_University
gptkb:Stanford_University
gptkb:University_of_Michigan
gptkb:Astellas_Pharma
|
|
gptkbp:receives_funding_from
|
gptkb:Series_A
gptkb:Series_B
$100 million
$300 million
$200 million
Series C
|
|
gptkbp:regulatory_compliance
|
gptkb:Dr._Sarah_L._Johnson
|
|
gptkbp:research
|
gptkb:Dr._Michael_H._Greenberg
|
|
gptkbp:research_focus
|
auditory neuroscience
otology
inner ear disorders
|
|
gptkbp:symbol
|
DBTX
|
|
gptkbp:technology
|
gptkb:physicist
small molecules
|
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
|
gptkbp:type
|
gptkb:Company
|
|
gptkbp:vision
|
restore hearing through innovative therapies
|
|
gptkbp:website
|
www.decibeltx.com
|